title: Treatment of eosinophilic esophagitis: how should we manage the disease?
abstract: Eosinophilic esophagitis (EE) is a chronic clinicopathologic syndrome and is the latest inflammatory disease of the esophagus described in literature. It seems to have a multifactorial etiology. Its causes include exposure to food or airborne allergens that affect individuals who may be genetically predisposed and exposure to the acid could also modulate the inflammatory response at esophageal level. However, we currently do not know how each of these possible etiologic factors contribute to the development of the disease that is essential to define specific treatment. We have used 3 different therapeutic approaches that were effective in patients with EE: various antiinflammatory drugs that are useful in treating asthma, controlling the exposure to allergens, particularly with respect to dietary changes and dilation of the esophagus. Although none of these treatments have absolute advantages, they can efficiently control the symptoms and inflammation in a large number of patients. Each treatment option should be assessed on a case-by-case basis in accordance with the experience of each center, the patients' characteristics, their sensitivity to allergens and their preferences. This article provides the latest information on the different treatment options for patients with EE, analyzing the advantages and disadvantages of each pathology and it offers practical recommendations on how to manage these patients who are being more frequently diagnosed.
authors.affiliation: Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso (Ciudad Real), Spain.
authors.forename: Sonia
authors.initials: S
authors.lastname: González-Castillo
authors.forename: Angel
authors.initials: A
authors.lastname: Arias
authors.forename: Alfredo J
authors.initials: AJ
authors.lastname: Lucendo
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D004032:Diet / Q000009:adverse effects; D057765:Eosinophilic Esophagitis / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D004945:Esophagoscopy; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D005765:Gastrointestinal Agents